Volume 7, Issue 1 (6-2020)                   vacres 2020, 7(1): 25-37 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Lundstrom K. The Potential of Self-amplifying RNA Vaccines for Infectious Diseases and COVID-19. vacres 2020; 7 (1) :25-37
URL: http://vacres.pasteur.ac.ir/article-1-202-en.html
PanTherapeutics
Abstract:   (3397 Views)
In addition to conventional vaccine development for infectious diseases, nucleic acid-based vaccine approaches have recently been presented as serious alternatives to previously used strategies based on live attenuated virus particles and subunit vaccines. Particularly, RNA-based vaccines have proven attractive. In this context, immunization with messenger RNA (mRNA) has provided strong immune responses and protection against challenges with lethal doses of pathogenic viruses in vaccinated animals. Alternatively, the efficient RNA replication mechanism provided by self-amplifying RNA (saRNA) viruses has been utilized. Enhanced immune responses with reduced doses required for immunization has been obtained in comparison to conventional mRNA administration. The rapid spread and destruction caused by the COVID-19 pandemic has substantially accelerated the demand for the development of robust and efficient vaccines against SARS-CoV-2. Both mRNA- and saRNA-based COVID-19 vaccine candidates are currently in human clinical trials.
Full-Text [PDF 617 kb]   (1435 Downloads)    
Type of Study: Review article | Subject: Vaccine development, efficacy and safety evaluation
Received: 2020/07/17

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 All Rights Reserved | Vaccine Research

Designed & Developed by : Yektaweb

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.